Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial

American Journal of Gastroenterology

Volumn 103, Issue 12, 2008, Pages 3132-3141

  Loftus, Edward V ^a   Feagan, Brian G ^b   Colombel, Jean Frédéric ^c   Rubin, David T ^d   Wu, Eric Q ^e   Yu, Andrew P ^e   Pollack, Paul F ^f   Chao, Jingdong ^f   Mulani, Parvez ^f  

^a MAYO CLINIC   (United States)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF CHICAGO   (United States)

^e ANALYSIS GROUP   (United States)

^f ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DEPRESSION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE SCALE; HUMAN; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SHORT FORM 36; VISUAL ANALOG SCALE; ZUNG SELF RATING DEPRESSION SCALE; DRUG ANTAGONISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 58149388237     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.02175.x     Document Type: Article

References (23)

1. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995 30 : 699 706.
2. Cohen RD. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther 2002 9 : 1603 9.
3. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: A systematic review of the literature. Am J Med 2004 116 (Suppl 7A 44S 9S.
4. Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: Results from the National Health Interview Survey. Am J Gastroenterol 2003 98 (5 1064 72.
5. Fuller-Thomson E, Sulman J. Depression and inflammatory bowel disease: Findings from two nationally representative Canadian surveys. Inflamm Bowel Dis 2006 12 : 697 707.
6. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989 96 : 804 10.
7. Rutgeerts P, Schreiber S, Feagan B, et al. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNF alpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis 2008 Mar 23 : 289 96.
8. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 30 : 473 83.
9. Feagan BG, Yan S, Bala M, et al. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003 98 : 2232 8.
10. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007 132 : 52 65.
11. Biggs JT, Wylie LT, Ziegler VE. Validity of the Zung self-rating depression scale. Br J Psychiatry 1978 132 : 381 5.
12. McDowell I, Newell C. Measuring health: A guide to rating scales and questionnaires, 2nd ed. New York : Oxford University Press, 1996.
13. Cella D, Lai JS, Chang CH, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002 94 : 2528 38.
14. Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: Properties, applications, and interpretation. Health Qual Life Outcomes 2003 1 : 79.
15. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994 106 : 287 96.
16. Pallis AG, Mouzas LA, Vlachonikolis IG. The inflammatory bowel disease questionnaire: A review of its national validation studies. Inflamm Bowel Dis 2004 10 : 261 9.
17. Irvine EJ. Development and subsequent refinement of the inflammatory bowel disease questionnaire: A quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999 28 : S23 7.
18. Gregor JC, McDonald JW, Klar N, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997 3 : 265 76.
19. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ 1992 305 : 160 4.
20. Ware JE Jr., Gandek B, Kosinski M, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: Results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998 51 : 1167 70.
21. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000 43 : 1478 87.
22. Surtees PG, Wainwright NW, Khaw KT, et al. Functional health status, chronic medical conditions and disorders of mood. Br J Psychiatry 2003 183 : 299 303.
23. Patrick DL, Gagnon DD, Zagari MJ, et al. Epoetin Alfa Study Group. Assessing the clinical significance of health-related quality of life (HRQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003 39 : 335 45.